In vivo application of recombinant interleukin 2 in the immunotherapy of established cytomegalovirus infection

We have shown in a murine model system for cytomegalovirus (CMV) disease in the immunocompromised host that in vivo application of recombinant human IL-2 (rhIL-2) can enhance the antiviral effect of a limited number of CD8+T lymphocytes, not only in prophylaxis, but also in therapy, when virus has already colonized host tissues. The observed net effect of IL-2 was consistent with the assumption of daily effector population doublings. The prospects for IL-2-supported immunotherapy of established CMV infection depend upon the tissues involved in disease. It appears that the prospects for controlling established CMV adrenalitis are less promising than for a therapy of interstitial CMV pneumonia.

[1]  S. Rosenberg,et al.  Results of clinical trials with the administration of interleukin 2 and adoptive immunotherapy with activated cells in patients with cancer. , 1986, Immunobiology.

[2]  J. Thompson,et al.  Potential uses of interleukin 2 in cancer therapy. , 1986, Immunobiology.

[3]  P. Greenberg,et al.  Antigen-driven long term-cultured T cells proliferate in vivo, distribute widely, mediate specific tumor therapy, and persist long- term as functional memory T cells , 1986, The Journal of experimental medicine.

[4]  S. Jonjić,et al.  Interstitial murine cytomegalovirus pneumonia after irradiation: characterization of cells that limit viral replication during established infection of the lungs , 1985, Journal of virology.

[5]  Niedt Gw,et al.  Acquired immunodeficiency syndrome. Clinicopathologic study of 56 autopsies. , 1985 .

[6]  B. Woda,et al.  Pathogenesis of murine cytomegalovirus infection in natural killer cell-depleted mice , 1984, Journal of virology.

[7]  M. Tapper,et al.  Adrenal necrosis in the acquired immunodeficiency syndrome. , 1984, Annals of internal medicine.

[8]  A. Fauci,et al.  Interleukin-2 enhances the depressed natural killer and cytomegalovirus-specific cytotoxic activities of lymphocytes from patients with the acquired immune deficiency syndrome. , 1983, The Journal of clinical investigation.

[9]  N. Flournoy,et al.  Cytomegalovirus infection and specific cell-mediated immunity after marrow transplant. , 1980, The Journal of infectious diseases.

[10]  A. Brody,et al.  Pathogenesis of pulmonary cytomegalovirus infection in immunosuppressed mice. , 1974, The Journal of infectious diseases.

[11]  J. B. Hanshaw.  Congenital cytomegalovirus infection: a fifteen year perspective. , 1971, The Journal of infectious diseases.

[12]  R. Schinella,et al.  Acquired immunodeficiency syndrome. Clinicopathologic study of 56 autopsies. , 1985, Archives of pathology & laboratory medicine.

[13]  U. Koszinowski,et al.  Significance of herpesvirus immediate early gene expression in cellular immunity to cytomegalovirus infection , 1984, Nature.